OLMA
Olema Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.75
+0.19%Next report
Analyst consensus
- Next report date
- Nov 9, 2026
- EPS estimate
- -$0.60
- Revenue estimate
- $1.3M
Latest reported
- Last report date
- Aug 10, 2026
- EPS actual
- -$0.61
- EPS estimate
- -$0.55
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 3
- EPS misses (12Q)
- 5
- EPS in line (12Q)
- 3
- Avg surprise (4Q)
- +2.8%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $47
- PT range
- $36 – $59
- Analysts
- 3
3 Buy0 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 9, 2026